Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial

or

Watchlist | Portfolio

quotes
- Price Overview
- Performance Report
charts
- Interactive Chart
- Snapshot Chart
technicals
company
analysts
- Earnings Estimates
- Analyst Ratings
financials

Neurosense Therapeutics Ltd (NRSN)

Neurosense Therapeutics Ltd (NRSN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] by (Cboe BZX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]

News & Headlines for [[ item.sessionDateDisplayLong ]]

NeuroSense CEO Provides Q3 2023 Update PR Newswire - Tue Oct 17, 2023

/PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today...

NeuroSense's PrimeC Demonstrates Outstanding Effect on ALS Survival in Innovative iPSC Model PR Newswire - Wed Oct 4, 2023

In collaboration with the University of Southern California's Ichida Stem Cell Lab, PrimeC was shown to significantly increase survival rate of induced motor...

NeuroSense Ends its At-The-Market Equity Offering Program: Company is Fully Funded Beyond Clinical Phase 2b ALS Results PR Newswire - Mon Oct 2, 2023

/PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today...

European Medicines Agency Grants NeuroSense SME Status PR Newswire - Wed Sep 20, 2023

/PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, announced...

NeuroSense to Host Investor Event in Cambridge, Massachusetts on July 24, 2023 PR Newswire - Mon Jul 17, 2023

/PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today...

NeuroSense CEO Provides Q2 2023 Update PR Newswire - Thu Jul 6, 2023

/PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today...

NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement PR Newswire - Thu Jun 22, 2023

/PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today...

NeuroSense Reports First Quarter 2023 Financial Results & Provides Business Update: Phase 2b ALS Trial Completes Enrollment, Topline Data Expected Q4 2023 PR Newswire - Thu Jun 1, 2023

/PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today...

NeuroSense Completes Enrollment in Phase 2b ALS Clinical Trial PR Newswire - Mon May 15, 2023

/PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today...

NeuroSense CEO Provides Q1 2023 Update: Phase 2b ALS Trial Achieves 80% Enrollment PR Newswire - Mon Apr 17, 2023

/PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today...

Barchart Exclusives

Nasdaq Market Has Perfect Bullish Historical Pattern – Don't Sell in May! Barchart - Sat May 18, 3:04PM CDT

"Sell in May and come back after Labor Day" is a well-known adage in the stock market that suggests investors should sell their stock holdings in May and return to the market after Labor Day in September. But, like so many market clichés, sayings that aren't supported by historical data are meaningless. An example is the upcoming Nasdaq seasonal buy with a perfect historical 15-year record. Will 2024 be the 16th year? Read more

Want to use this as
your default charts setting?

Save this setup as a Chart Templates

Switch the Market flag

for targeted data from your country of choice.

Open the menu and switch the
Market flag for targeted data from your country of choice.

Want Streaming Chart Updates?

Switch your Site Preferences
to use Interactive Charts

Need More Chart Options?

Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar